ATE220718T1 - Mutierte ras peptide zur zeugung von cd8+ zytitoxischen t lymphoizyten - Google Patents

Mutierte ras peptide zur zeugung von cd8+ zytitoxischen t lymphoizyten

Info

Publication number
ATE220718T1
ATE220718T1 AT97921247T AT97921247T ATE220718T1 AT E220718 T1 ATE220718 T1 AT E220718T1 AT 97921247 T AT97921247 T AT 97921247T AT 97921247 T AT97921247 T AT 97921247T AT E220718 T1 ATE220718 T1 AT E220718T1
Authority
AT
Austria
Prior art keywords
lymphoicytes
cytitoxic
generate
ras
identified
Prior art date
Application number
AT97921247T
Other languages
English (en)
Inventor
Jeffrey Schlom
Scott Abrams
Original Assignee
Us Gov Sec Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Sec Health filed Critical Us Gov Sec Health
Application granted granted Critical
Publication of ATE220718T1 publication Critical patent/ATE220718T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464464—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97921247T 1996-04-19 1997-04-17 Mutierte ras peptide zur zeugung von cd8+ zytitoxischen t lymphoizyten ATE220718T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63534496A 1996-04-19 1996-04-19
PCT/US1997/006470 WO1997040156A1 (en) 1996-04-19 1997-04-17 Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes

Publications (1)

Publication Number Publication Date
ATE220718T1 true ATE220718T1 (de) 2002-08-15

Family

ID=24547410

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97921247T ATE220718T1 (de) 1996-04-19 1997-04-17 Mutierte ras peptide zur zeugung von cd8+ zytitoxischen t lymphoizyten

Country Status (8)

Country Link
US (1) US8883448B2 (de)
EP (1) EP0895538B1 (de)
AT (1) ATE220718T1 (de)
AU (1) AU2734397A (de)
DE (1) DE69714033T2 (de)
DK (1) DK0895538T3 (de)
ES (1) ES2180045T3 (de)
WO (1) WO1997040156A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019112B1 (en) 1996-03-19 2006-03-28 University Of Virginia Patent Foundation Peptides recognized by melanoma-specific A1-, A2- and A3-restricted cytoxic lymphocytes, and uses therefor
EP0966480A2 (de) * 1997-01-30 1999-12-29 The University Of Virginia Patent Foundation Cystein-reduzierte peptide, welche durch a3-limitierte zytotoxische lymphozyten erkannt werden, sowie anwendungen
GB2328689A (en) * 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
GB9907860D0 (en) * 1999-04-07 1999-06-02 Smithkline Beecham Biolog Novel compounds
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
AU2003301021C1 (en) 2002-12-16 2010-02-18 Globelmmune, Inc. Yeast-based vaccines as immunotherapy
AU2012261237B2 (en) 2011-05-24 2017-06-01 BioNTech SE Individualized vaccines for cancer
WO2013167136A1 (en) 2012-05-08 2013-11-14 Herlev Hospital Improving adoptive cell therapy with interferon gamma
EP2925348B1 (de) 2012-11-28 2019-03-06 BioNTech RNA Pharmaceuticals GmbH Individualisierte impfstoffe gegen krebs
WO2015123532A1 (en) * 2014-02-16 2015-08-20 Globeimmune, Inc. Ras g12r immunotherapy for ras mutation-positive cancers
US10973894B2 (en) * 2014-10-02 2021-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
JP7419268B2 (ja) * 2018-03-02 2024-01-22 エリシオ セラピューティクス， インク． 変異ｋｒａｓ配列及び脂質を含む化合物並びにその使用
KR20210119468A (ko) * 2019-01-25 2021-10-05 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 돌연변이체 ras를 표적화하기 위한 조성물 및 방법
WO2020210202A1 (en) * 2019-04-11 2020-10-15 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039948A (en) 1973-05-07 2000-03-21 The Ohio State University Method for treatment of antigenically modified polypeptides
US5643565A (en) 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
DE68917126T2 (de) 1988-02-01 1995-02-02 Praxis Biolog Inc T-zellen-epitope als träger für einen konjugierten impfstoff.
GB8924438D0 (en) 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
US5861372A (en) 1996-02-22 1999-01-19 The Children's Medical Center Corporation Aggregate angiostatin and method of use

Also Published As

Publication number Publication date
DE69714033D1 (de) 2002-08-22
EP0895538B1 (de) 2002-07-17
AU2734397A (en) 1997-11-12
DK0895538T3 (da) 2002-11-04
ES2180045T3 (es) 2003-02-01
EP0895538A1 (de) 1999-02-10
DE69714033T2 (de) 2003-02-13
US8883448B2 (en) 2014-11-11
WO1997040156A1 (en) 1997-10-30
US20100074945A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
ATE220718T1 (de) Mutierte ras peptide zur zeugung von cd8+ zytitoxischen t lymphoizyten
ATE298367T1 (de) Interleukin-15 antagoniste
ATE181337T1 (de) Therapeutisch nützliche peptide und peptidfragmente
ATE267211T1 (de) Impfstoff gegen hpv
IT1229721B (it) Dispositivo di supporto a treppiede inclinabile, in particolare per supportare oggetti come strumenti musicali e/o simili.
DK1210430T3 (da) MUC-1-afledte peptider
DE69935866D1 (de) Auf N-Formyl Methionyl Peptide basierendem Adjuvans für Impfstoffe
DK0810870T3 (da) Isolerede, MAGE-2-afledte tumorafstødelsesantigenpræcurserpeptider og anvendelse heraf
UA85365C2 (ru) Продукт конъюгирования цитокина для использования в противораковой терапии
DK1447414T3 (da) Antagonistpeptider af carcinoembronisk antigen (CEA)
NO952385D0 (no) Fremgangsmåte til identifisering av individer med unormale celler som uttrykker HLA-A2/tyrosinasepeptidantigen
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
AU1086888A (en) Primary biliary cirrhosis autoantigen
EP0836480A4 (de) Zusammensetzungen, welche adp-ribosyltransferase-aktivität ausweisen und methoden für ihre herstellung und die verwendung derselben
DK0952771T3 (da) Hidtil ukendte saponinpræparater og anvendelser deraf
SE9501512D0 (sv) Synthetic peptide-defined eptopes useful for vaccination against papillomavirus
IT1303823B1 (it) Composizioni farmaceutiche a base di proteine.
DE60237588D1 (de) Neue trp2-isoform mit cytotoxischen t-lymphozyten-epitopen mit hla-a2-restriktion
MXPA03004436A (es) Proteinas bcl-2 mutantes y sus usos.
IT238518Y1 (it) Base per sedie,poltroncine o simili
IT7822816V0 (it) Piedistallo di base per poltroncina o sedia da ufficio.
IT218381Z2 (it) Struttura di supporto dello schienale di poltrone, divani e simili, variamente posizionabile.
IT8605138A1 (it) Dispositivo di supporto ad altezza regolabile particolarmente per sedie, poltrone, sgabelli e simili
LV5208A3 (lv) Preseti izstradajumi uz pirogeni ieguta silicija dioksida bazes to izgatavosanas metode un to pielietosana
MX9706412A (es) Uso de aerogeles inorganicos en la industria farmaceutica.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties